CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures

Open access

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a common, progressive liver disease strongly associated with the metabolic syndrome. It is unclear how progression of NAFLD towards cirrhosis translates into systematic changes in circulating proteins. Here, we provide a detailed proteo-transcriptomic map of steatohepatitis and fibrosis during progressive NAFLD. In this multicentre proteomic study, we characterize 4,730 circulating proteins in 306 patients with histologically characterized NAFLD and integrate this with transcriptomic analysis in paired liver tissue. We identify circulating proteomic signatures for active steatohepatitis and advanced fibrosis, and correlate these with hepatic transcriptomics to develop a proteo-transcriptomic signature of 31 markers. Deconvolution of this signature by single-cell RNA sequencing reveals the hepatic cell types likely to contribute to proteomic changes with disease progression. As an exemplar of use as a non-invasive diagnostic, logistic regression establishes a composite model comprising four proteins (ADAMTSL2, AKR1B10, CFHR4 and TREM2), body mass index and type 2 diabetes mellitus status, to identify at-risk steatohepatitis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s42255-023-00775-1

Cites

Statistics

Figures

Fig. 1 Proteomics analysis from patients with histologically proven NAFLD to identify circulating markers. a, Schematic overview of the study. b,c, Differentially expressed proteins in the discovery cohort of 191 patients stratified on the basis of fibrosis stage F3–4 versus baseline F0–2 (Benjamini–Hochberg false discovery rate) (b) and functional annotation enrichment analysis (c). d,e, Differentially expressed proteins in 191 patients stratified on the basis of a high disease activity score NAS ≥ 4 (Benjamini–Hochberg false discovery rate) (d) and enrichment analysis (e). f, Venn diagram showing overlap between the two different analyses. g, Heatmap showing expression of top 50 most significant proteins associated with fibrosis and NAS ≥ 4. FC, fold change. Source data
Fig. 1 Proteomics analysis from patients with histologically proven NAFLD to identify circulating markers. a, Schematic overview of the study. b,c, Differentially expressed proteins in the discovery cohort of 191 patients stratified on the basis of fibrosis stage F3–4 versus baseline F0–2 (Benjamini–Hochberg false discovery rate) (b) and functional annotation enrichment analysis (c). d,e, Differentially expressed proteins in 191 patients stratified on the basis of a high disease activity score NAS ≥ 4 (Benjamini–Hochberg false discovery rate) (d) and enrichment analysis (e). f, Venn diagram showing overlap between the two different analyses. g, Heatmap showing expression of top 50 most significant proteins associated with fibrosis and NAS ≥ 4. FC, fold change. Source dataCC BY · PubMed Central
Fig. 2 Proteo-transcriptomics correlation. a, Pearson correlation analysis between plasma proteome (4,584 protein probes, matching 4,292 proteins and/or genes) and matching hepatic mRNA in a subset of the discovery cohort (n = 52). b, Integrated single-cell RNA-seq analysis to deconvolute the 31 signatures of proteins associated with hepatic mRNA.
Fig. 2 Proteo-transcriptomics correlation. a, Pearson correlation analysis between plasma proteome (4,584 protein probes, matching 4,292 proteins and/or genes) and matching hepatic mRNA in a subset of the discovery cohort (n = 52). b, Integrated single-cell RNA-seq analysis to deconvolute the 31 signatures of proteins associated with hepatic mRNA.CC BY · PubMed Central
Fig. 3 Non-invasive diagnostic tool to identify patients with at-risk NASH. a, Binary logistic regression modelling identified a composite model in the discovery cohort (n = 191 patients) that could classify patients with at-risk NASH on the basis of the variables BMI, T2DM and circulating ADAMTSL2, AKR1B10, CFHR4 and TREM2. b, Performance of the classification model in two independent cohorts (discovery n = 191 patients, validation n = 115 patients) in comparison with NFS, Fibrosis-4 (FIB-4) and AST:ALT ratio. Bar charts present AUC for each score with the corresponding standard error of area, as calculated by ROC analysis. Paired-sample area difference under the ROC curve test was used to compare the classification model with the other scores (discovery cohort NFS P = 0.000001, FIB-4 P = 7.8667 × 10−7 and AST:ALT ratio P = 6.85 × 10−10; validation cohort NFS P = 0.000429, FIB-4 P = 0.000949 and AST:ALT ratio P = 0.000036) (****P < 0.0001, ***P < 0.001). c, Representative images of immunohistochemistry and quantification for AKR1B10 in human liver biopsies (n = 30 biologically independent patient samples). Scale bars, 100 μm. Data are presented as mean ± s.e.m. (Kruskal–Wallis with Bonferroni correction and Mann–Whitney U-test). Arrows indicate necro-inflammatory region with ballooned hepatocytes. Source data
Fig. 3 Non-invasive diagnostic tool to identify patients with at-risk NASH. a, Binary logistic regression modelling identified a composite model in the discovery cohort (n = 191 patients) that could classify patients with at-risk NASH on the basis of the variables BMI, T2DM and circulating ADAMTSL2, AKR1B10, CFHR4 and TREM2. b, Performance of the classification model in two independent cohorts (discovery n = 191 patients, validation n = 115 patients) in comparison with NFS, Fibrosis-4 (FIB-4) and AST:ALT ratio. Bar charts present AUC for each score with the corresponding standard error of area, as calculated by ROC analysis. Paired-sample area difference under the ROC curve test was used to compare the classification model with the other scores (discovery cohort NFS P = 0.000001, FIB-4 P = 7.8667 × 10−7 and AST:ALT ratio P = 6.85 × 10−10; validation cohort NFS P = 0.000429, FIB-4 P = 0.000949 and AST:ALT ratio P = 0.000036) (****P < 0.0001, ***P < 0.001). c, Representative images of immunohistochemistry and quantification for AKR1B10 in human liver biopsies (n = 30 biologically independent patient samples). Scale bars, 100 μm. Data are presented as mean ± s.e.m. (Kruskal–Wallis with Bonferroni correction and Mann–Whitney U-test). Arrows indicate necro-inflammatory region with ballooned hepatocytes. Source dataCC BY · PubMed Central
Extended Data Fig. 1 Exploration of confounding effects on the expression of Soma probes. Differentially expressed Soma probes after correction for sex and centre in the discovery cohort (n = 191) stratified based on fibrosis, NAS ≥ 4 and T2DM. The lower panel provides an overview showing the effect of corrections on the probe expression.
Extended Data Fig. 1 Exploration of confounding effects on the expression of Soma probes. Differentially expressed Soma probes after correction for sex and centre in the discovery cohort (n = 191) stratified based on fibrosis, NAS ≥ 4 and T2DM. The lower panel provides an overview showing the effect of corrections on the probe expression.CC BY · PubMed Central
Extended Data Fig. 2 Tissue expression analysis of the 31 proteo-transcriptome signature based on GTEx portal. Expression of the hepatic 31 proteo-transcriptome signature in different organs based on GTEx portal.
Extended Data Fig. 2 Tissue expression analysis of the 31 proteo-transcriptome signature based on GTEx portal. Expression of the hepatic 31 proteo-transcriptome signature in different organs based on GTEx portal.CC BY · PubMed Central
Extended Data Fig. 3 Performance of non-invasive scores to identify patients with NASH + F ≥ 2 + NAS ≥ 4. Comparison of the classification model, FibroScan-AST (FAST), NAFLD fibrosis score (NFS), Fibrosis-4 (FIB-4) and AST/ALT ratio in a subset of the discovery, n = 62 (a), and validation, n = 28 (b), cohort. Bar charts present Area under the Curve (AUC) for each score with the corresponding standard error of area, as calculated by Receiver operating characteristic (ROC) analysis. Paired-Sample Area Difference under the ROC curve test was used to compare the classification model with other scores (discovery cohort FAST p = 0.111826, NFS p = 0.050406, FIB-4 p = 0.003247 and AST/ALT ratio p = 0.016038; validation cohort FAST p = 0.045552, NFS p = 0.038341, FIB-4 p = 0.036835 and AST/ALT ratio p = 0.005652) (**p < 0.01, *p < 0.05).
Extended Data Fig. 3 Performance of non-invasive scores to identify patients with NASH + F ≥ 2 + NAS ≥ 4. Comparison of the classification model, FibroScan-AST (FAST), NAFLD fibrosis score (NFS), Fibrosis-4 (FIB-4) and AST/ALT ratio in a subset of the discovery, n = 62 (a), and validation, n = 28 (b), cohort. Bar charts present Area under the Curve (AUC) for each score with the corresponding standard error of area, as calculated by Receiver operating characteristic (ROC) analysis. Paired-Sample Area Difference under the ROC curve test was used to compare the classification model with other scores (discovery cohort FAST p = 0.111826, NFS p = 0.050406, FIB-4 p = 0.003247 and AST/ALT ratio p = 0.016038; validation cohort FAST p = 0.045552, NFS p = 0.038341, FIB-4 p = 0.036835 and AST/ALT ratio p = 0.005652) (**p < 0.01, *p < 0.05).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 20 · Cited by 178

Metadata

Authors
Govaere, O., Hasoon, M., Alexander, L., Cockell, S., Tiniakos, D., Ekstedt, M., Schattenberg, J. M., Boursier, J., Bugianesi, E., Ratziu, V., LITMUS Investigators, Daly, A. K., & Anstee, Q. M.
Affiliations
  • Universitair Ziekenhuis Leuven (BE)
  • Newcastle University (GB)
  • SomaLogic (United States) (US)
  • National and Kapodistrian University of Athens (GR)
  • Linköping University (SE)
  • University Medical Center of the Johannes Gutenberg University Mainz (DE)
  • University of Turin (IT)
  • Sorbonne Université (FR)
  • NIHR Newcastle Biomedical Research Centre (GB)
  • Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
Corresponding author
Anstee, Quentin M.
Venue
Nature Metabolism
Published
2023-04-10
Volume
5
Issue
4
Pages
572-578
ISSN
2522-5812 (ISSN-L)
OpenAlex
W4363676289
Cited by
178
References
20
Citations by year
2026: 58 · 2025: 60 · 2024: 47 · 2023: 13
FWCI
35.53
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Metabolism (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
  • Lirias (submittedVersion, other-oa)
  • DiVA (Linkoping University) (submittedVersion, other-oa)
  • HAL (submittedVersion)
  • Newcastle University ePrints (Newcastle Univesity) (cc-by)
Funders
  • EC | Horizon 2020 Framework Programme (634413)
  • Innovative Medicines Initiative (777377)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
non-alcoholic fatty liver disease, steatohepatitis, liver fibrosis, circulating proteins, non-invasive diagnosis, ADAMTSL2, AKR1B10, TREM2, disease progression, metabolic syndrome, type 2 diabetes, body mass index
MeSH terms
ADAMTS Proteins, Aldo-Keto Reductases, Single-Cell Gene Expression Analysis, Adult, Aged, Apolipoproteins, Diabetes Mellitus, Type 2, Fatty Liver, Female, Humans, Immunohistochemistry, Liver Cirrhosis, Male, Membrane Glycoproteins, Middle Aged, Receptors, Immunologic, Registries, Cohort Studies, Body Mass Index, Logistic Models, Disease Progression, Gene Expression Profiling, Proteomics, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures. https://app.cochat.ai/papers/10.1038/s42255-023-00775-1
The paper
Govaere, O., Hasoon, M., Alexander, L., Cockell, S., Tiniakos, D., Ekstedt, M., Schattenberg, J. M., Boursier, J., Bugianesi, E., Ratziu, V., LITMUS Investigators, Daly, A. K., & Anstee, Q. M. (2023). A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures. Nature Metabolism. https://doi.org/10.1038/s42255-023-00775-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.